Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Zensho Ito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8069-8984; OpenAlex author ID A5032750544. Sources: OpenAlex.

Their work

Papers
11 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide… Co-author DOI 10.1136/jitc-2024-011426↗
  2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable … Co-author DOI 10.1136/jitc-2024-009765↗
  3. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-021-08911-4↗
  4. Cancerous pericarditis presenting as cardiac tamponade in a 68-year-old man with pancreatic adenocarcinoma: a case report. First author DOI 10.1186/s13256-020-02546-y↗
  5. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. First author DOI 10.1080/07357907.2019.1661427↗
  6. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Co-author DOI 10.1159/000500359↗
  7. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2018.8961↗
  8. Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.6071↗
  9. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour sit… First author DOI 10.3109/00365521.2015.1121515↗
  10. Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model. Co-author DOI 10.1371/journal.pone.0142981↗
  11. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for p… Co-author PMID 25550602↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeo Koido · 11 shared papers, 2015–2025 · strength 1.03
  2. Masayuki Saruta · 7 shared papers, 2018–2025 · strength 0.84
  3. Haruo Sugiyama · 7 shared papers, 2015–2025 · strength 0.76
  4. Toshifumi Ohkusa · 5 shared papers, 2017–2025 · strength 0.63
  5. Shigetaka Shimodaira · 4 shared papers, 2018–2025 · strength 0.53
  6. Shin Kan · 5 shared papers, 2015–2024 · strength 0.48
  7. Masamori Shimabuku · 2 shared papers, 2024–2025 · strength 0.38
  8. Mikio Kajihara · 6 shared papers, 2015–2019 · strength 0.34
  9. Shuichi Fujioka · 4 shared papers, 2017–2021 · strength 0.32
  10. Masato Okamoto · 5 shared papers, 2015–2019 · strength 0.31
  11. Kazuki Takakura · 5 shared papers, 2015–2018 · strength 0.26
  12. Sachie Kiryu · 2 shared papers, 2020–2021 · strength 0.23
  13. Shintaro Tsukinaga · 1 shared paper, 2024 · strength 0.18
  14. Tomoya Kanai · 3 shared papers, 2016–2018 · strength 0.18
  15. Sayumi Yoshida · 2 shared papers, 2019 · strength 0.16
  16. Sadamu Homma · 2 shared papers, 2015 · strength 0.09
  17. Sumiyuki Nishida · 1 shared paper, 2018 · strength 0.07
  18. Koichiro Haruki · 1 shared paper, 2016 · strength 0.05
  19. Takeshi Gocho · 1 shared paper, 2016 · strength 0.05
  20. Yuki Fujiwara · 1 shared paper, 2016 · strength 0.05
  21. Hisao Tajiri · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.